<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02276196</url>
  </required_header>
  <id_info>
    <org_study_id>DC2014ELIX001</org_study_id>
    <nct_id>NCT02276196</nct_id>
  </id_info>
  <brief_title>Effect of LIXIsenatide on the Renal System</brief_title>
  <acronym>ELIXIRS</acronym>
  <official_title>A Phase 4, Mono-center, Randomized, Open Label, Comparator-controlled, Parallel-group, Mechanistic Intervention Trial to Assess the Effect of 8-week Treatment With the Glucagon-like Peptide-1 Receptor Agonist Lixisenatide Versus Insulin Glulisine on Renal Physiology and Biomarkers in Insulin Glargine-treated Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on preclinical and small-sized studies in non-diabetic individuals, incretin-based&#xD;
      therapies, i.e. glucagon-like peptide (GLP)-1 receptor agonists and dipeptidyl peptidase-4&#xD;
      inhibitors, may hold promise in preventing the onset and progression of diabetic kidney&#xD;
      disease. However, the potential renoprotective effects of these agents, that are believed to&#xD;
      be effectuated &quot;beyond glucose control&quot;, have not been sufficiently detailed in human&#xD;
      diabetes.&#xD;
&#xD;
      Therefore, the present study aims to explore the mechanistic and clinical effects of GLP-1&#xD;
      receptor agonists on renal physiology and biomarkers in patients with type 2 diabetes.&#xD;
&#xD;
      Forty patients with insulin-treated type 2 diabetes will undergo an eight week intervention&#xD;
      with lixisenatide or insulin glulisine in order to assess changes in the outcome parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes from baseline following 8-week treatment with a glucagon-like peptide(GLP)-1 receptor agonist versus insulin glulisine on renal hemodynamics, measured as glomerular filtration rate (GFR) / effective renal plasma flow (ERPF)</measure>
    <time_frame>8 weeks</time_frame>
    <description>ml/min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal damage, measured by urine biomarkers</measure>
    <time_frame>8 weeks</time_frame>
    <description>enzyme immuno assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal tubular function</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. percentage (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Body anthropometrics: body weight, height, body mass index, waist circumference</measure>
    <time_frame>8 weeks</time_frame>
    <description>kilogram, meters, centimeters</description>
  </other_outcome>
  <other_outcome>
    <measure>Body fat content</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. percentage (%)</description>
  </other_outcome>
  <other_outcome>
    <measure>Glycemic variables</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. mmol/l, mmol/mol</description>
  </other_outcome>
  <other_outcome>
    <measure>Lipid spectrum</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. mmol/l</description>
  </other_outcome>
  <other_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. nmol/l</description>
  </other_outcome>
  <other_outcome>
    <measure>Systemic hemodynamic variables</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. ml/min</description>
  </other_outcome>
  <other_outcome>
    <measure>Heart rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>beat per minute</description>
  </other_outcome>
  <other_outcome>
    <measure>Microvascular function</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. count</description>
  </other_outcome>
  <other_outcome>
    <measure>Arterial stiffness</measure>
    <time_frame>8 weeks</time_frame>
    <description>e.g. augmentation index</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Diabetic Kidney Disease</condition>
  <condition>Diabetic Nephropathy</condition>
  <condition>Diabetes Mellitus</condition>
  <condition>Glucagon-Like Peptide 1</condition>
  <arm_group>
    <arm_group_label>Lixisenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lixisenatide will be administered subcutaneously, once daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin glulisine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glulisine will be administered subcutaneously, once daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lixisenatide</intervention_name>
    <description>GLP-1 receptor agonist</description>
    <arm_group_label>Lixisenatide</arm_group_label>
    <other_name>Lyxumia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glulisine</intervention_name>
    <description>Insulin analogue</description>
    <arm_group_label>Insulin glulisine</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with type 2 diabetes (HbA1c: 6.5-10.0% or 48-86 mmol/mol)&#xD;
&#xD;
          -  Stable treatment with basal insulin glargine (dose ±20%) and metformin or basal&#xD;
             insulin glargine (dose ±20%) alone for at least 3 months&#xD;
&#xD;
          -  Fasting plasma glucose &lt;10 mmol/L or the use of &gt;50 units of basal insulin glargine&#xD;
&#xD;
          -  Females must be post-menopausal&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
          -  Age: 35 - 75 years&#xD;
&#xD;
          -  Body Mass Index: &gt;25 kg/m2&#xD;
&#xD;
          -  Hypertension should be under control, i.e. &lt;140/90 mmHg, and treated with an&#xD;
             angiotensin-converting enzyme inhibitor or angiotensin-II-receptor blocker for at&#xD;
             least 3 months.&#xD;
&#xD;
          -  Albuminuria should be treated with an angiotensin-converting enzyme inhibitor (ACE-I)&#xD;
             or angiotensin-II-receptor blocker (ARB) for at least 3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current/chronic use of the following medication: thiazolidinediones, sulfonylurea&#xD;
             derivatives, GLP-1 receptor agonists, dipeptidyl peptidase (DPP)-4 inhibitors,&#xD;
             glucocorticoids, immune suppressants, antimicrobial agents, chemotherapeutics,&#xD;
             antipsychotics, tricyclic antidepressants and monoamine oxidase inhibitors. Subjects&#xD;
             on diuretics, will only be excluded when these drugs cannot be stopped for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Chronic use of non-steroidal anti-inflammatory drugs will not be allowed, unless used&#xD;
             as incidental medication (1-2 tablets) for non-chronic indications (i.e. sports&#xD;
             injury, head-ache or back ache). However, no such drugs can be taken within a&#xD;
             time-frame of 2 weeks prior to renal-testing&#xD;
&#xD;
          -  Hypoglycemia unawareness based on investigator judgment&#xD;
&#xD;
          -  History of severe hypoglycemia that required emergency hospital treatment within 3&#xD;
             months prior to screening&#xD;
&#xD;
          -  Estimated GFR &lt;60 mL/min/1.73m2 (determined by the Modification of Diet in Renal&#xD;
             Disease (MDRD) study equation)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Current urinary tract infection and active nephritis&#xD;
&#xD;
          -  Recent (&lt;6 months) history of cardiovascular disease, including: acute coronary&#xD;
             syndrome, chronic heart failure (New York Heart Association grade II-IV), stroke or&#xD;
             transient ischemic neurologic disorder&#xD;
&#xD;
          -  Complaints compatible with or established gastroparesis, neurogenic bladder and/or&#xD;
             incomplete bladder emptying (as determined by ultrasonic bladder scan)&#xD;
&#xD;
          -  Active liver disease or a 3-fold elevation of liver enzymes (aspartate&#xD;
             aminotransferase/alanine aminotransferase) at screening&#xD;
&#xD;
          -  History of or actual pancreatic disease&#xD;
&#xD;
          -  History of or actual malignancy (except basal cell carcinoma)&#xD;
&#xD;
          -  History of or actual severe mental disease&#xD;
&#xD;
          -  Substance abuse (alcohol: defined as &gt;4 units/day)&#xD;
&#xD;
          -  Allergy to any of the agents used in the study&#xD;
&#xD;
          -  Individuals who are investigator site personnel, directly affiliated with the study,&#xD;
             or are immediate (spouse, parent, child, or sibling, whether biological or legally&#xD;
             adopted) family of investigator site personnel directly affiliated with the study&#xD;
&#xD;
          -  Inability to understand the study protocol or give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>VU Universtiy Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2014</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>M.H.H. Kramer</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin glulisine</mesh_term>
    <mesh_term>Lixisenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

